Showing results (121-130 of 220) with videos related to

Sort By:
Pageof 22
Neurology|March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based StudyTim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 21, 2018
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosisMyintzu Min, Tim Spelman, Alessandra Lugaresi, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 27, 2024
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBaseTim Spelman, Sara Eichau, Raed Alroughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 9, 2020
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS scoreAmy Kunchok, Jeannette Lechner-Scott, Franco Granella, et al.
Neurology|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term DisabilitySifat Sharmin, Izanne Roos, Pierre M Labauge, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 17, 2019
Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT studyLisanne J Balk, Danko Coric, Benjamin Knier, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched studyBassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practiceTim Spelman, Claire Meyniel, Juan Ignacio Rojas, et al.
Multiple Sclerosis and Related Disorders|December 20, 2025
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-studyHelmut Butzkueven, Pamela Farr, Serkan Ozakbas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registryTim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Pageof 22